Glucagon-Like Peptide 1 Receptor Agonists (GLP1RA) and Sodium-glucose co- transporter-2 inhibitors (SGLT2i): Making a pragmatic choice in diabetes management

被引：1

作者：

Kalra, Sanjay ^{[1
]}

Bhattacharya, Saptarshi ^{[2
]}

Kapoor, Nitin ^{[3
,4
]}

机构：

[1] Bharti Hosp, Dept Endocrinol, Karnal, India

[2] Max Hosp, Dept Endocrinol, New Delhi, India

[3] Christian Med Coll & Hosp, Dept Endocrinol Diabet & Metab, Vellore, Tamil Nadu, India

[4] Univ Melbourne, Melbourne Sch Populat & Global Hlth, Nossal Inst Global Hlth, Non Communicable Dis Unit, Melbourne, Vic, Australia

来源：

JOURNAL OF THE PAKISTAN MEDICAL ASSOCIATION | 2022年 / 72卷 / 05期

关键词：

Canagliflozin; CV risk reduction; dapagliflozin; dulaglutide; empagliflozin; GLP1RA; liraglutide; obesity; semaglutide; SGLT2i;

D O I：

10.47391/JPMA.22-64

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The availability of newer glucose-lowering drugs has created opportunities for comprehensive diabetes care. Two classes of drugs, GLP1RA (glucagon-like peptide 1 receptor agonists), and SGLT2i (sodium glucose cotransporter 2 inhibitors) have demonstrated their efficacy in glucose control as well as cardiovascular risk reduction. While both can be used together, there is an ongoing debate regarding their relative advantages and limitations. We present a clinical perspective to compare and control these two classes of drugs, and promote rational prescription in diabetes praxis.

引用

页码：989 / 990

页数：2

共 6 条

[1] 6. Glycemic Targets: Standards of Medical Care in Diabetes-2021 [J].